{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:50:14Z","timestamp":1792227014117,"version":"4.4.0"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1001\/jamadermatol.2020.1795","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T15:02:17Z","timestamp":1593615737000},"page":"1079","source":"Crossref","is-referenced-by-count":35,"title":["Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center"],"prefix":"10.1001","volume":"156","author":[{"given":"Zizi","family":"Yu","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Christopher","family":"Dee","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Q.","family":"Bach","sequence":"additional","affiliation":[{"name":"Division of Dermatology, University of California, Los Angeles Medical Center, Santa Monica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"20","key":"doi200035r1","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer.","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"doi200035r2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"doi200035r3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clcc.2017.12.004","article-title":"Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review.","volume":"17","author":"Lacouture","year":"2018","journal-title":"Clin Colorectal Cancer"},{"issue":"11","key":"doi200035r4","first-page":"34","article-title":"Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist\u2019s perspective: impact on health-related quality of life and implications for clinical management of psychological sequelae.","volume":"21","author":"Wagner","year":"2007","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"doi200035r5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.","volume":"102","author":"Eilers","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"3-4","key":"doi200035r6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"issue":"3","key":"doi200035r7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000277656","article-title":"Treatment of epidermal growth factor receptor antagonist\u2013induced skin rash: results of a survey among German oncologists.","volume":"33","author":"Hassel","year":"2010","journal-title":"Onkologie"},{"issue":"5","key":"doi200035r8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3892\/mco.2015.586","article-title":"Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin.","volume":"3","author":"Horie","year":"2015","journal-title":"Mol Clin Oncol"},{"issue":"8","key":"doi200035r9","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"doi200035r10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/fon.14.251","article-title":"Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.","volume":"11","author":"Kobayashi","year":"2015","journal-title":"Future Oncol"},{"issue":"34","key":"doi200035r11","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"doi200035r12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor\u2013associated dermatologic toxicities.","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"issue":"12","key":"doi200035r13","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1634\/theoncologist.2016-0051","article-title":"Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumors.","volume":"21","author":"Hofheinz","year":"2016","journal-title":"Oncologist"},{"issue":"199","key":"doi200035r14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005886","article-title":"Epidermal EGFR controls cutaneous host defense and prevents inflammation.","volume":"5","author":"Lichtenberger","year":"2013","journal-title":"Sci Transl Med"},{"issue":"22","key":"doi200035r16","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Per\u00e9z-Soler","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"doi200035r17","first-page":"489","article-title":"Epidermal growth factor receptor inhibitor skin rash prophylaxis in a community oncology setting.","volume":"9","author":"Pepper","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"doi200035r15","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Published November 27, 2017. Accessed May 21, 2020. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2767661\/jamadermatology_yu_2020_oi_200035_1602515648.93353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T15:51:33Z","timestamp":1602690693000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2767661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.1795","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}